multiple sclerosis

Sanofi-Aventis, Genzyme on the Brink of a Merger

It seems that months of merger talks between French pharmaceutical company Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 per share for the rare disease drugmaker, with an option included potentially worth $5 to $6 a share.

Sanofi Says MS Drug Reduces Relapses

French pharmaceutical giant Sanofi-Aventis says its multiple sclerosis drug teriflunomide significantly cut relapses in patients who took the once-daily oral treatment.

Impressive Results for Two New MS Pills

There is still no cure for the chronic disease multiple sclerosis, but separate late-stage studies on two different experimental drugs show them both to be effective at slowing it down. If approved by the FDA, the pills will be the first oral treatments available for the disease.